EDIT Editas Medicine, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 5, 2026
$2,62
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$1,67rendah 52m
$4,54tinggi 52m
Kapitalisasi Pasar (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Pendapatan (TTM)
$47M
lencana Anda
Rentang 52M
$2–$5
Peringkat Analis
BUY
Target Harga
$6
P/E
-4.0
ROE
-118.8%
Margin Laba Bersih
-157.3%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
EDIT Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$2.62
Kapitalisasi Pasar (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Pendapatan (TTM)
$47M
ROE (TTM)
-118.8%
D/E Utang/Ekuitas (MRQ)
0.5
Rentang 52M
$2–$5
EDIT Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang Editas Medicine, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan87
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$41M2016-12-31 → 2025-12-31
EPS$-1.802019-12-31 → 2025-12-31
Arus Kas Bebas$-166M2016-12-31 → 2025-12-31
Margin bersih-157.3%2018-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | EDIT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -4.0rata-rata 5T ≈-3.7 | ≈-3.7 | · | · | |
| P/S (TTM) | 5.5rata-rata 5T ≈24.2 | ≈24.2 | 11.6 | Kurang nilai | |
| P/B (MRQ) | 2.4rata-rata 5T ≈3.1 | ≈3.1 | 2.2 | Terlalu mahal | |
| EV / EBITDA | -1.1 | · | · | · | |
| Harga / FCF (TTM) | -2.1rata-rata 5T ≈-4.3 | ≈-4.3 | · | · | |
| Harga / Arus Kas (TTM) | -2.1rata-rata 5T ≈-4.5 | ≈-4.5 | · | · | |
| EV / Pendapatan (TTM) | 2.1 | · | · | · | |
| EV / FCF (TTM) | -0.8 | · | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 9.4rata-rata 5T ≈3.1 | ≈3.1 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | EDIT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -161.4%rata-rata 5T ≈-658.2% | ≈-658.2% | -334.4% | Tingkat teratas | |
| EBITDA Margin (Margin EBITDA) | -394.9%rata-rata 5T ≈-658.2% | ≈-658.2% | -334.4% | Tingkat teratas | |
| Margin Laba Bersih (TTM) | -157.3%rata-rata 5T ≈-639.3% | ≈-639.3% | -300.0% | Tingkat teratas | |
| ROA (TTM) | -33.0%rata-rata 5T ≈-43.0% | ≈-43.0% | -47.0% | Lemah | |
| ROE (TTM) | -118.8%rata-rata 5T ≈-195.1% | ≈-195.1% | -63.2% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | EDIT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | 0.5 | · | 0.0 | Utang tinggi | |
| Rasio Lancar (MRQ) | 3.2rata-rata 5T ≈5.9 | ≈5.9 | 5.6 | Likuiditas rendah | |
| Rasio Cepat (MRQ) | 3.1rata-rata 5T ≈5.8 | ≈5.8 | 4.2 | Likuiditas rendah | |
| Utang Jangka Panjang / Ekuitas (MRQ) | 0.5 | · | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | EDIT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 25.4%rata-rata 5T ≈33.7% | ≈33.7% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 27.2%rata-rata 5T ≈10.1% | ≈10.1% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | -14.9% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | EDIT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.2rata-rata 5T ≈0.1 | ≈0.1 | 0.1 | Tingkat teratas | |
| Receivables Turnover (Perputaran Piutang) | 2.6rata-rata 5T ≈6.1 | ≈6.1 | · | · | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$465.7K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
2.8%
Laporan Berikutnya
Nov 09, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 10, 2026 | $-0.15 | $-0.28 | 45.5% |
| 31 Maret 2026 | Mei 11, 2026 | $-0.26 | $-0.27 | 3.3% |
| 31 Des. 2025 | $-0.06 | $-0.26 | 77.2% | |
| 30 Sep. 2025 | $-0.28 | $-0.30 | 7.3% | |
| 30 Juni 2025 | $-0.63 | $-0.38 | -63.8% | |
| 31 Maret 2025 | $-0.92 | $-0.60 | -53.1% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $1.62 | $4.27 | $5.24 | $8.09 | $6.29 | $4.83 | $4.84 | $4.68 | $3.76 | |
| Revenue / Share | $0.46 | $0.39 | $1.03 | $0.29 | $0.38 | · | · | · | · | · | |
| Cash Flow / Share | $-1.86 | $-2.55 | $-1.74 | $-2.58 | $-2.42 | · | · | · | · | · | |
| Cash / Share | $1.50 | $1.59 | $1.51 | $2.06 | $2.97 | $2.23 | $4.38 | $2.76 | $3.29 | $5.17 | |
| EPS (TTM) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $42.0K | $6M | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $41M | $44M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $16M | $17M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $58M | $61M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-58M | $-54M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $1.0K | $235.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-56M | $-53M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | $-58M | $-54M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $211M | $169M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | $209M | $283M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | $120.0K | $713.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | $7M | $8M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | $427M | $461M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | $15M | $16M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | $36M | $35M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | $20M | $19M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | $8M | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | $7M | $6M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | $19M | $20M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | $42M | $36M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | $9M | $10M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | $116M | $115M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | $-1.02B | $-962M | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | $-4M | $-3M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $415M | $465M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | 68,761,729 | 68,718,434 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $6M | $7M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-48M | $-38M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $614.0K | $632.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $89M | $-4M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $80.0K | $367.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $41M | $-41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | -132681.0% | -840.2% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | -8.9% | -8.0% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | -11.1% | -9.9% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | 10.1 | 12.7 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | 9.9 | 12.4 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | 0.2 | 12.2 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $0.04 | · | $0.14 | $0.22 | $0.75 | · | $2.13 | $2.81 | $3.58 | · | $4.41 | $4.90 | $4.60 | $6.03 | $6.77 | |
| Revenue / Share | $0.10 | $0.03 | · | $0.08 | $0.04 | $0.06 | · | $0.00 | $0.01 | $0.01 | · | $0.07 | $0.04 | $0.14 | $0.00 | $0.09 | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $-0.58 | · | · | · | $-0.61 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.86 | $1.26 | · | $1.78 | $1.59 | $1.66 | · | $1.16 | $0.78 | $0.84 | · | $1.01 | $2.71 | $1.87 | $3.06 | $2.47 | |
| EPS (TTM) | $-0.66 | $-1.14 | · | $-2.38 | $-2.85 | $-3.04 | · | $-2.53 | $-2.33 | $-2.07 | · | $-2.70 | $-2.96 | $-3.18 | $-2.94 | $-2.70 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $47M | $39M | · | $46M | $39M | $36M | · | $62M | $67M | $69M | · | $25M | $19M | $23M | $26M | $32M | |
| Net Income TTM | $-74M | $-109M | · | $-200M | $-237M | $-251M | · | $-211M | $-193M | $-166M | · | $-195M | $-206M | $-219M | $-201M | $-184M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | $842M | $813M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.9 | -2.2 | · | -1.5 | -0.8 | -0.4 | · | -1.3 | -2.0 | -3.6 | · | -2.9 | -2.8 | -2.3 | -4.2 | -4.4 | |
| P/S | 6.7 | 6.2 | · | 7.0 | 4.9 | 2.7 | · | 4.6 | 5.7 | 8.8 | · | 25.9 | 34.8 | 21.9 | 32.8 | 25.6 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| EV / Revenue | 3.4 | 4.5 | · | 4.7 | 1.8 | -1.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -20.4% | -46.2% | · | -68.6% | -129.6% | -262.1% | · | -74.2% | -49.9% | -27.9% | · | -34.6% | -36.0% | -43.9% | -24.0% | -22.8% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $41M | $32M | $78M | $20M | $26M |
| Margin Operasi % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Laba Bersih | $-160M | $-237M | $-153M | $-220M | $-193M |
| EPS Dilusian | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | 2.1 | 0.4 | · | · | · |
| Rasio Lancar | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Rasio Cepat | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-166M | $-219M | $-137M | $-181M | $-172M |
Pemilik institusional (13F) 236 pengaju · $406.3M total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
236
Nilai yang dipegang
$406.3M
Posisi baru
38
Posisi yang keluar
23
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 38 (-7 vs Kuartal sebelumnya) | 23 (-3 vs Kuartal sebelumnya) | 80 (+22 vs Kuartal sebelumnya) | 42 (-8 vs Kuartal sebelumnya) | +68.9M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 8,86% | Saham |
| BlackRock, Inc. | $34.311.568 | 10.589.990 | 8,44% | Saham |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 7,09% | Saham |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 7,09% | Saham |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 7,09% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 4,90% | Saham |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 4,45% | Saham |
| VANGUARD GROUP INC | $16.826.539 | 8.208.068 | 4,14% | Saham |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,08% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 2,87% | Saham |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 2,84% | Saham |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 2,83% | Saham |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 2,49% | Saham |
| GOLDMAN SACHS GROUP INC | $8.469.476 | 2.614.036 | 2,08% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $8.325.643 | 2.569.072 | 2,05% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 1,97% | Saham |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 1,77% | Saham |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 1,75% | Saham |
| MARSHALL WACE, LLP | $6.600.808 | 2.037.287 | 1,62% | Saham |
| D. E. Shaw & Co., Inc. | $6.159.246 | 1.901.002 | 1,52% | Saham |
| JPMORGAN CHASE & CO | $5.959.980 | 1.862.494 | 1,47% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $5.094.065 | 1.572.242 | 1,25% | Saham |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,06% | Saham |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,06% | Saham |
| RAYMOND JAMES FINANCIAL INC | $4.273.389 | 1.318.947 | 1,05% | Saham |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 0,82% | Saham |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,70% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,69% | Saham |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,68% | Saham |
| NORTHERN TRUST CORP | $2.655.806 | 819.693 | 0,65% | Saham |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,62% | Saham |
| UBS Group AG | $2.432.472 | 750.763 | 0,60% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,59% | Saham |
| Nuveen, LLC | $1.688.730 | 521.213 | 0,42% | Saham |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,40% | Saham |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,38% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,37% | Opsi beli |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,37% | Saham |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,35% | Saham |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,33% | Saham |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,32% | Opsi beli |
| MORGAN STANLEY | $1.108.616 | 342.165 | 0,27% | Saham |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,26% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $1.002.440 | 309.395 | 0,25% | Saham |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,24% | Saham |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,22% | Saham |
| Bank of New York Mellon Corp | $850.907 | 262.625 | 0,21% | Saham |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,18% | Saham |
| LPL Financial LLC | $748.813 | 231.115 | 0,18% | Saham |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,18% | Saham |
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 pengajuan | 18 Sep. 2017 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 35 orang dalam · 17 pejabat · 17 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 Sep. 2026 S | 243.189 | 0 | 4 | $-80.045 |
| MULLEN JAMES C | CEO | 14 April 2022 A | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 Feb. 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 Jan. 2019 S | 1.204.966 | 0 | 0 | $0 |
| Amy Parison | SVP, Chief Financial Officer | 3 Sep. 2026 S | 13.839 | 0 | 5 | $-6.327 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 8 Maret 2025 A | 112.720 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 11 Mei 2023 S | 106.610 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 Feb. 2019 M | 0 | 0 | 0 | $0 |
| Daniel Scott Ory | EVP, Chief Medical Officer | 8 Sep. 2026 A | · | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 3 Sep. 2026 S | 61.660 | 0 | 5 | $-20.333 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 3 Des. 2024 S | 133.354 | 0 | 0 | $0 |
| Bruce Eaton | EVP, CBO AND CTO | 5 Des. 2023 S | 74.791 | 0 | 0 | $0 |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER | 13 Feb. 2023 S | 65.559 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 Des. 2021 A | 22.675 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 Okt. 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 Maret 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 Feb. 2018 A | 4.000 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | Direktur | 6 Agu 2026 A | · | 0 | 0 | $0 |
| Elliott M. Levy | Direktur | 17 Juni 2026 A | · | 0 | 0 | $0 |
| David Scadden | Direktur | 17 Juni 2026 A | · | 0 | 0 | $0 |
| Bernadette Connaughton | Direktur | 17 Juni 2026 A | · | 0 | 0 | $0 |
| Jessica Hopfield | Direktur | 17 Juni 2026 A | 67.700 | 0 | 0 | $0 |
| Andrew Hirsch | Direktur | 17 Juni 2026 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | Direktur | 30 Mei 2024 A | · | 0 | 0 | $0 |
| Emma Reeve | Direktur | 30 Mei 2024 A | · | 0 | 0 | $0 |
| Akshay Vaishnaw | Direktur | 30 Mei 2024 A | · | 0 | 0 | $0 |
| Boris Nikolic | Direktur | 15 Juni 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Direktur | 17 Agu 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Direktur | 15 Juni 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Direktur | 15 Juni 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Direktur | 15 Juni 2017 A | · | 0 | 0 | $0 |
| Kevin P Starr | Pemilik 10% | 6 Sep. 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Pemilik 10% | 8 Feb. 2016 C | 2.649.572 | 0 | 0 | $0 |
| Charles Albright | · | 15 Des. 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | · | 15 Maret 2017 M | 117.788 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 17 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 39.171 SH | 2 Okt. 2026 | Harian |
| IWC · iShares Trust | 0,06% | 339.728 SH | 11 Sep. 2026 | Harian |
| IBB · iShares Trust | 0,03% | 1.101.092 SH | 11 Sep. 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 11.076 SH | 1 Okt. 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 19 Agu 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 170.052 SH | 2 Okt. 2026 | Harian |
| IWO · iShares Trust | 0,02% | 844.017 SH | 11 Sep. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,01% | 2.588.297 SH | 11 Sep. 2026 | Harian |
| RSSL · Global X Funds | 0,01% | 47.823 NS | 31 Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.230 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 19 Agu 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 19 Agu 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 19 Agu 2026 | Harian |
| IWN · iShares Trust | · | 120.579 SH | 11 Sep. 2026 | Harian |
EDIT Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 18 analis
BELI
Target median
$5.00
+90,8%
5 27,8%
Beli Kuat
7 38,9%
Beli
4 22,2%
Tahan
2 11,1%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
10 analis · 2026-09-27Target rata-rata $5.90 +125,2%
Sekarang
Harga saat ini $2.62
Rendah$1.00
Rata-rata$5.90
Tinggi$15.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| EIKN | · | · | · | · | · | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 5, 2026